FibroGen’s Pamrevlumab Failed to Meet its Primary Endpoints in P-III Trial (LELANTOS-1) for the Treatment of Duchenne Muscular Dystrophy
Shots:
- The P-III trial evaluating pamrevlumab vs PBO in combination with systemic corticosteroids in 99 non-ambulatory patients aged ≥12yrs. with DMD on background corticosteroids
- The study failed to meet its 1EPs of performance of the upper limb 2.0 (PUL 2.0) score @52wk. over baseline, was safe and well tolerated and the majority of TEAEs were mild or mod. The study results will be presented at an upcoming medical conference
- The P-III trial (LELANTOS-2) results of pamrevlumab are expected in Q3’23 for ambulatory patients with DMD. The therapy received ODD & FTD for IPF, DMD, and LAPC; RPD designation from the US FDA for DMD; ODD from the EMA for DMD
Ref: Globenewswire | Image: Fibrogen
Related News:- FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
